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Ly6d-L, a Cell Surface Ligand for Mouse Ly6d
(Gumley et al., 1994). Recently, E48, the human homologJim Apostolopoulos,* Ian F. C. McKenzie,
and Mauro S. Sandrin for Ly6d, has been described (Brakenhoff et al., 1995).
Here we describe the identification of mouse Ly6d-LMolecular Immunogenetics and Transplantation
Laboratory and the isolation of cDNA clones encoding this ligand.
It is a 76±amino acid (9 kDa) protein found on the cellAustin Research Institute
Kronheimer Building surface in association with a 30 kDa protein.




Production of Recombinant Soluble Ly6d Protein
Previous studies have shown that an unidentified ligand
for Ly6A.2 was present on the cell surface of thymocytes
Summary (Bamezai and Rock, 1995). In this study, we considered
that it was also possible that the ligand for murine Ly6d
The mouse Ly6 gene family encodes proteins found was a cell surface molecule expressed on lymphocytes.
in lymphocytes and other cells. Some are involved in To identify this ligand, recombinant soluble Ly6d was
cell activation; no ligands have been found. A ligand produced, and in binding assays, this protein bound to
for Ly6d (ThB) was identified on lymphocytes using the cell surface of lymphocytes. A COS cell transfection/
microspheres loaded with Ly6d and the cDNA isolated expression system was used to isolate cDNA clones for
from a spleen/thymus library by panning on Ly6d. The Ly6d-L by panning (Seed and Aruffo, 1987). To do these
Ly6d ligand (Ly6d-L) is a nonglycosylated protein of 9 experiments, Ly6d cDNA was modified by removal of
kDa of broad distribution, rich in cysteine, with no the GPI anchor and addition of His6 and FLAG tags atdiscernable transmembrane sequence. Its N and C the C terminus, prior to transfection of Sf21 cells. A
termini are on the cell surface, where it associates baculovirus expression system was then used to ex-
with a 30 kDa protein. Ly6d-L is homologous with an press soluble recombinant Ly6d. Ly6d was purified from
EGF repeat of Notch. the supernatant, and analysis by SDS-PAGE indicated
a single Ly6d protein band with Mr of approximately
11 kDa (Figure 1A) and pI 6.4 (as determined by 2DIntroduction
electrophoresis, data not shown). Mass spectrometry
of the purified protein (Figure 1B), including the His6-The murine Ly6 family contains glycosylphosphatidyl-
FLAG sequences, indicated that the observed molecularinositol (GPI) anchored cell surface membrane glycopro-
weight (10,135 Da) was identical to the predicted molec-teins (Ly6A/E, Ly6B, Ly6C, Ly6F, Ly6G) found on hemo-
ular weight of nonglycosylated Ly6d lacking the leaderpoietic and other cells (McKenzie et al., 1977; Echhardt
sequence. N-terminal sequencing of the first ten aminoand Herzenberg, 1980; Hogarth et al., 1984; Kimura et
acids of the purified protein contained the sequenceal., 1984; Sutton et al., 1985; Gumley et al., 1995) and
Leu-Arg-Cys-His-Val-Cys-Thr-Asn-Ser-Ala, providing theencoded by a gene complex on chromosome 15 (Ho-
first protein sequence of Ly6d and supporting the pre-garth et al., 1984). Ly6 molecules are involved in cellular
diction (Gumley et al., 1995) that the leader peptide isinteractions and T cell activation (Rock et al., 1986; Flood
cleaved at the Leu1 position in the mature protein (Figureet al., 1990; Izon et al., 1996), and Ly6A/E and Ly6C are
1B). The purified soluble recombinant protein was thenupregulated by interferon-g and CD3 stimulation (Malek
used to identify and isolate the ligand for Ly6d.et al., 1989; Lee et al., 1994). The overexpression of
Ly6A.2 in transgenic mice demonstrated that Ly6A.2 is
involved in cell adhesion (Bamezai and Rock, 1995) and The Binding of Multimeric Ly6d Microspheres
its regulated expression is important for T cell develop- to Lymphocytes
ment (Bamezai et al., 1995). In addition, Ly6C regulates To demonstrate that lymphocytes expressed Ly6d-L
endothelial adhesion and homing of CD81 T cells by and could therefore bind recombinant Ly6d, a binding
activating integrin-dependent adhesion pathways (Han- assay was established using multimeric Ly6d-coated
ninen et al., 1997). No ligand for any mouse Ly6 molecule fluorescent microspheres and C57BL/6 lymphocytes. To
has been identified. establish the assay, mouse CD48, GFP (green fluores-
Ly6d is expressed exclusively on thymocytes and cent protein), and sheep anti-mouse IgG microspheres
splenic B cells; we have previously isolated cDNA for were used; CD48-coated microspheres bound to CD2
murine Ly6d (Gumley et al., 1992) and analyzed its poly- on z50% of splenocytes or thymocytes (Figure 1C), their
morphism. There are two Ly6d alleles, Ly6dhigh and binding being completely inhibited by preincubating the
Ly6dlow, that control the level of expression (Echhardt microspheres with anti-CD48 antibody (Figure 1C). Fur-
and Herzenberg, 1980) by different rates of transcription ther, sheep anti-mouse IgG-coated microspheres bound
to 50% of splenocytes (B cells) but not to thymocytes
(Figure 1C); GFP microspheres or microspheres alone* To whom correspondence should be addressed (e-mail: j.apostolo
poulos@ari.unimelb.edu.au). (data not shown) did not bind to cells. This assay was
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Figure 1. Analysis of Recombinant Ly6d
(A) Silver-stained SDS-PAGE (15% acryl-
amide) of recombinant soluble Ly6d (1 mg)
following purification with Talon resin and
FPLC.
(B) Mass spectrometry and N-terminal se-
quencing (box) of purified soluble Ly6d. A mi-
nor species (-K) in the spectrogram repre-
sents the C-terminal cleavage of a lysine.
(C) Binding of fluorescent multimeric protein
microsphere complexes to lymphocytes. Multi-
meric microspheres were bound to Ly6d,
CD48, GFP, or sheep anti-mouse IgG (as indi-
cated) and incubated with lymphocytes. In
blocking studies, the relevant microspheres
were preincubated with anti-Ly6d, anti-CD48,
or 10 mg of recombinant soluble Ly6d (rsLy6d)
prior to binding with lymphocytes, as de-
scribed in Experimental Procedures. The per-
centage of cells binding microspheres was
determined by dividing the number of cells
binding microspheres by the number of total
cells in each field (SEM). All assays were per-
formed in triplicate.
therefore considered suitable for examining the interac- although the microspheres could be agglutinated by the
further addition of anti-mouse Ig.tion of recombinant Ly6d with its ligand.
It was then shown that C57BL/6 lymphocytes could Thus, thymocytes and splenocytes bind Ly6d and ex-
press a ligand for Ly6d and were used as a source ofbind Ly6d-coated microspheres, presumably by the
Ly6d ligand (Ly6d-L). There was binding of Ly6d-loaded cDNA to isolate Ly6d-L.
microspheres to 90% 6 4% (SEM) of thymocytes and
to 73% 6 2% of splenocytes (Figure 1C). This binding
could be completely inhibited by the preincubation of Isolation and Characterization of Ly6d-L cDNA
To isolate Ly6d-L cDNA, a C57BL/6 spleen and thymusmicrospheres with monoclonal anti-Ly6d antibody or
competitively inhibited by preincubating lymphocytes cDNA library and a COS cell expression system were
used (Seed and Aruffo, 1987). After COS cell transfectionwith recombinant soluble Ly6d (Figure 1C). In these
assays there was no agglutination of the Ly6d micro- with the cDNA library and four cycles of panning on
purified recombinant soluble Ly6d, plasmid DNA wasspheres when they were incubated with Ly6d antibody,
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Figure 2. Sequence Analysis of Ly6d-L
(A) DNA sequence of a Ly6d-L clone. ª11º
indicates the start of the coding region and
asterisks represents the stop codon TAA.
(B) Identification of a short repeat in Ly6d-L
as indicated by amino acid positions.
(C) Amino acid alignment and homology
(boxes) between Ly6d-L and Motch.
isolated from 12 clones and sequenced. The DNA se- this sequence. Although Ly6d-L contains an Asn four
residues from the C-terminal end of the molecule, thequences were identical in all clones (Figure 2A) and
contained a 575 base pair (bp) cDNA insert: an 81 bp succeeding run of hydrophobic residues typical of GPI
anchoring are not present. It was not clear if the Gln21-59 untranslated region preceding an open reading frame
of 231 bp (the longest open reading frame) and suc- Leu39 segment could be a transmembrane region; there-
fore, it was likely that Ly6d-L is maintained at the plasmaceeded by a 263 bp 39 untranslated segment. Sequence
analysis of the 231 bp open reading frame showed it membrane by other mechanisms (see below). There are
no N-linked glycosylation sites within the protein se-encodes a 76±amino acid protein with a predicted mo-
lecular mass of 9112 Da. As shown later (Figure 7C, lane quence; however, the molecule may be O-linked glyco-
sylated as there are five Ser and two Thr residues.3), this is the true size of the protein. The predicted
protein sequence of Ly6d-L does not contain a leader Ly6d-L also contains five Cys residues that could be
involved in intra- and interchain disulphide bonds. Nosequence (characteristic of type I integral membrane
proteins) nor a conventional transmembrane region. The consensus motifs were found; however, an 8±amino acid
sequence, with the consensus sequence Met-Ile-Met-longest stretch of hydrophobic residues, using the Kyte-
Doolittle algorithm, occurs from Gln21 to Leu39, is flanked Xxx-Val-Leu-Xxx-Cys, is repeated within Ly6d-L (Fig-
ure 2B).by the charged residues Arg20 (at the N-terminal end)
and Asp40 (at the C-terminal end), and contains charged Ly6D-L was analyzed for amino acid sequence ho-
mology to other proteins by performing a BLASTPresidues Arg30His31, which are located in the middle of
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analyzed by probing a mouse poly(A)1 RNA master blot
(Figure 3B). Ly6d-L was detected in all tissues: brain,
eye, liver, lung, kidney, heart, skeletal muscle, smooth
muscle, pancreas, thyroid, thymus, submaxillary gland,
spleen, testis, ovary, prostate, epididymis, and uterus.
The strongest expression was in testis (D1) and liver
(A3). In the developing embryo, there was expression
of Ly6d-L in day 7 embryo (E1). This was followed by
decreased expression at days 11, 15, and 17. Southern
analysis of C57BL/6 genomic DNA (Figure 3C) detected
a single band z8.5 kb following EcoRI (lane 1), BamHI
(lane 2), or PstI (lane 3) digestion, consistent with a single
copy gene.
Binding Studies with Ly6d-L- and Ly6d-Transfected
COS Cells
Further evidence that Ly6d-L is indeed a specific cell
surface ligand for Ly6d was obtained by using a COS
cell expression system, now possible following isolation
of the Ly6d-L cDNA. To show that Ly6d-L was expressed
Figure 3. Expression of Ly6d-L in Various Tissues on the cell surface, inferred from the binding of Ly6d
(A) Northern analysis of 10 mg of total RNA from various tissues microspheres to lymphocytes, a FLAG tag was added
probed with 32P-labeled Ly6d-L cDNA. Lanes: (1) liver, (2) spleen, to the N- or C-terminal ends of the Ly6d-L cDNA and
(3) brain, and (4) thymus. This Northern was also probed with 32P- then expressed in COS cells. Detection with an anti-
labeled g-actin. FLAG antibody clearly indicated the cell surface expres-
(B) Equal amounts of Poly(A)1 RNA were loaded on a blot and probed
sion of both the N- and C-terminal-FLAG Ly6d-L (Figureswith 32P-labeled Ly6d-L cDNA. A1, brain; A2, eye; A3, liver; A4, lung;
4A and 4B, respectively). The presence of Ly6d-L onA5, kidney; B1, heart; B2, skeltal muscle; B3, smooth muscle; C1,
pancreas; C2, thyroid; C3, thymus; C4, submaxillary gland; C5, the surface of transfected COS cells was further exam-
spleen; D1, testis; D2, ovary; D3, prostate; D4, epididymis; D5, ined with the microsphere-binding assay. Ly6d micro-
uterus; E1, day 7 embryo; E2, day 11 embryo; E3, day 15 embryo; spheres bound to the surface of Ly6d-L1 COS cells
E4, day 17 embryo. (Figure 5A); this binding was inhibited by incubating
(C) Southern analysis: 10 mg of genomic C57BL/6 DNA was digested
Ly6d-L1 COS cells with 10 mg of recombinant solublewith EcoRI (lane 1), BamHI (lane 2), or PstI (lane 3), followed by
Ly6d prior to adding Ly6d microspheres (Figure 5B).electrophoresis in a 1% agarose gel and probing with 32P-labeled
Ly6d-L cDNA. Incubating the Ly6d microspheres with monoclonal anti-
Ly6d antibody prior to their addition to Ly6d-L1 COS
cells also blocked binding (Figure 5C). In control experi-
search of the nonredundant protein databases (Gen- ments, Ly6d-L1 COS cells bound Ly6d microspheres
Bank CDS translations, PDB, SwissProt, SPupdate, and preincubated with an isotype control antibody (Figure
PIR): one protein sequence gave significant alignment, 5D) prior to their incubation with COS cells. In addition,
an EGF-like repeat region of the mouse neurogenic Ly6d-L1 COS cells did not bind with GFP (an irrelevant
Notch homolog precursor Motch (Figure 2C). Ly6d-L has protein) microspheres or microspheres (no protein bound)
33% identity with one Motch EGF-like repeat and 52% alone (data not shown). Control plasmid±transfected
homology when conservative substitutions are allowed. COS cells did not bind Ly6d microspheres (Figure 5E).
The Motch protein contains 36 tandemly arranged EGF- To confirm that Ly6d-L was indeed a ligand for Ly6d,
like repeats, believed to be involved in ligand binding C57BL/6 splenic T cells and B cells were obtained and
(Apella et al., 1988; Campbell, 1998). We note that the Ly6d2 (Figure 4D) and Ly6d1 (Figure 4E) cells isolated.
ligands for Ly6-related human CD59 and uPAR, as well Thymocytes (Figure 5F) and Ly6d1 splenic B cells (Fig-
as the mouse uPAR, contain EGF-like repeats (Gumley ure 5G) bound to Ly6d-L1 COS cells; however, splenic
et al., 1995). Searching the dbEST database with the full Ly6d2 T cells (Figure 5K) did not bind to Ly6d-L1 COS
coding region of Ly6d-L retrieved several sequences cells. The binding of Ly6d1 B cells with Ly6d-L1 COS
such as those from 3.5 day mouse blastocyst (accession cells was inhibited by incubation of Ly6d-L1 COS cells
number C78210), 16-cell mouse embryo (accession with recombinant soluble Ly6d (Figure 5H) or by incuba-
number AU043968), and unfertilized mouse eggs (acces- tion of B cells with the Ly6d antibody (Figure 5I) but not
sion number AA426777). These nucleotide sequences by incubation of B cells with an isotype control antibody
were identical to the nucleotide sequence encoding (Figure 5J). Similarly, the binding of thymocytes to
Ly6d-L. Ly6d-L1 COS cells was inhibited by soluble Ly6d or by
Ly6d antibody but not by incubation of thymocytes with
a control antibody (data not shown). Mock-transfectedDNA and RNA Analysis
Northern analysis of total RNA (Figure 3A) detected a COS cells did not bind Ly6d1 B cells (Figure 5L) or
thymocytes (data not shown).single 1.9 kb band of Ly6d-L mRNA in liver (lane 1),
spleen (lane 2), thymus (lane 4), and weakly in brain (lane In the reciprocal experiment, thymocytes (Figure 6A)
and B cells (Figure 6B) bound to Ly6d1 COS cells. Thy-3). There was equal loading of RNA in each lane, as
indicated by g-actin (Figure 3A). Expression was further mocyte (data not shown) and B cell binding to Ly6d1
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Figure 4. Transfection of COS Cells with FLAG-Tagged Ly6d-L cDNA
Transfection of COS Cells with either N-terminal (A) or C-terminal (B) FLAG-tagged Ly6d-L cDNA. (C) COS cells were transfected with pCDM8
plasmid only. Detection was performed with anti-FLAG antibody followed by rat a-mouse Ig-FITC and microscopy (magnification 3200). In
addition, purified BL/6 spleen T cells (D) and B cells (E) were analyzed by flow cytometry. Antibodies were used to detect T cells (anti-CD3),
B cells (anti-CD45R), and Ly6d1/2 (anti-Ly6d) cells. Control cells were incubated with a control isotype monoclonal antibody.
COS cells was inhibited by incubation of lymphocytes was no staining with anti-FLAG (Figure 4C). This finding
indicated that Ly6d-L was not a type I (transmembranewith recombinant soluble Ly6d (Figure 6C) or by preincu-
bation of COS cells with blocking anti-Ly6d antibody with extracellular N terminus and cytoplasmic C termi-
nus), a type II (transmembrane with extracellular C termi-(Figure 6D) but not by incubation of Ly6d1 COS cells with
a control isotype antibody (Figure 6E). Mock-transfected nus and cytoplasmic N terminus), nor a type III (cyto-
plasmic N and C termini with multipass transmembrane)COS cells did not bind B cells (Figure 6F) or thymocytes
(data not shown). It is of interest to note that Ly6d2 T cell surface protein. Second, whether Ly6d-L was a type
V cell surface protein (GPI anchored with extracellularcells express Ly6d-L and bind to Ly6d1 COS cells (Fig-
ure 6G), consistent with the observation that Ly6d-L is N and C termini) was investigated by treatment of the
Ly6d-L1 COS cells with the GPI anchor cleaving enzymeexpressed in a wider range of tissues than is Ly6d (Fig-
ure 3B). Splenic T cell binding to Ly6d-transfected COS phosphatidylinositol phospholipase C (PIPLC). In con-
trol experiments, COS cells were transfected with FLAG-cells was inhibited by preincubation of splenic T cells
with recombinant soluble Ly6d (Figure 6H) or by preincu- tagged CD48 and treated with PIPLC, which led to its
disassociation into the supernatant (Figure 7A, lane 5).bation of Ly6d-transfected COS cells with blocking anti-
Ly6d antibody (Figure 6I) but not by preincubation of CD48 was detected in the lysate of untreated cells also
(Figure 7A, lane 8) but was absent in mock transfectionsLy6d1 COS cells with a control isotype antibody (Figure
6J). Mock-transfected COS cells did not bind splenic T (Figure 7A, lanes 9±12). The PIPLC experiments with
Ly6d-L1 COS cells showed that Ly6d-L is not GPI an-cells (Figure 6K).
chored, as no detectable Ly6d-L protein was found in
the supernatant of PIPLC-treated cells (Figure 7A, laneMode of Ly6d-L Cell Surface Attachment
The mechanism by which Ly6d-L is anchored to the cell 1). In addition, Ly6d-L1 COS cell lysates treated (Figure
7A, lane 3) or untreated (Figure 7A, lane 4) with PIPLCsurface was examined by transfecting COS cells with
Ly6d-L cDNA containing a FLAG sequence at either the contain Ly6d-L. Further, there was no evidence that
Ly6d-L is normally secreted, since the media from threeN or C terminus. First, both the N-FLAG (Figure 4A) or
C-FLAG (Figure 4B) Ly6d-L-transfected cells gave cell separate Ly6d-L transfections was negative (Figure 7B,
lanes 1±3). Ly6d-L protein was, however, present in thesurface staining with the FLAG antibody, indicating that
both N and C termini were extracellular. It was noted lysate of these Ly6d-L1 COS cells (Figure 7B, lane 4).
On the cell surface, Ly6d-L is associated with anotherthat in control studies with mock transfectants, there
Immunity
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Figure 5. Binding Studies with Ly6d-L-Trans-
fected COS Cells and Multimeric Ly6d Micro-
spheres or Lymphocytes
The Ly6d-L1 COS cells were incubated with
(A) Ly6d microspheres, (B) 10 mg of recombi-
nant soluble Ly6d and then with Ly6d micro-
spheres, (C) Ly6d microspheres preincubated
with anti-Ly6d antibody, or (D) Ly6d micro-
spheres preincubated with control isotype
antibody. In addition, pCDM8-transfected
COS cells were incubated with (E) Ly6d mi-
crospheres. Ly6d-L1-transfected COS cells
were also incubated with (F) thymocytes, (G)
splenic B cells, (H) 10 mg of recombinant solu-
ble Ly6d then incubated with splenic B cells,
(I) splenic B cells preincubated with anti-Ly6d
antibody, (J) splenic B cells preincubated
with control isotype antibody, or (K) splenic T
cells. Plasmid pCDM8±transfected COS cells
were incubated with (L) purified splenic B
cells. Binding was examined by light micros-
copy (A±E at 2003; F±L at 1003).
protein, demonstrated by the biotinylation of the cell Discussion
surface of Ly6d-L1 COS cells, followed by immunopre-
cipitation with anti-FLAG antibodies and SDS-PAGE We describe the identification and cloning of Ly6d-L, a
9 kDa ligand for Ly6d that is present on the surface of(Figure 7C). In a reducing gel following detection with
streptavidin-HRP, Ly6d-L was 9 kDa in size (Figure 7C, thymocytes and splenocytes and in other cells (e.g.,
pancreas, thymus, spleen, reproductive tissues, lung,lane 3) and coimmunoprecipitated with a 30 kDa protein
(Figure 7C, lane 3); the two proteins associate as 40 kDa liver, and heart). In our approach to identify a ligand for
Ly6d, it was considered that the ligand, like Ly6d itself,on the cell surface (nonreducing gel, Figure 7C, lane 3),
indicating a possible covalent association. The same could be a cell surface molecule found on lymphocytes
similar to other cell surface molecules such as CD2-samples were also stained with anti-FLAG antibody and
identified Ly6d-L in the reducing gel as a 9 kDa protein CD48, CD4-MHC class II, CD8-MHC class I, and TCR-
MHC. To investigate this, the first step involved the pro-(Figure 7C, lane 4) and in the nonreducing gel (Figure
7C, lane 4) as part of the 40 kDa complex. No proteins duction of recombinant mouse Ly6d, which was also
useful to formally identify, by N-terminal sequencing,were detected in nonreducing or reducing gels in mock-
transfected COS cells immunoprecipitated with anti- that the leader sequence is cleaved at the previously
predicted Leu21 residue (Gumley et al., 1995). Further-FLAG antibody (Figure 7C, lanes 1 and 5) or in Ly6d-L-
transfected COS cells immunoprecipitated with an more, the observed 10,135 Da mass of the purified Ly6d
(determined by mass spectrometry) demonstrated thatcontrol isotype antibody (Figure 7C, lanes 2 and 6). Thus,
Ly6d-L associates on the cell surface either covalently the recombinant material is nonglycosylated, in keeping
with the observation that Ly6d does not contain N-linkedor noncovalently with a 30 kDa protein, whose identity
remains to be determined. glycosylation sites (Gumley et al., 1995). Clearly, there
Ly6d-L, a Ligand for Mouse Ly6d
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Figure 6. Binding Studies with Ly6d-Trans-
fected COS Cells and Lymphocytes
COS cells were transfected with Ly6d cDNA
and incubated with (A) thymocytes, (B)
splenic B cells, (C) splenic B cells preincu-
bated with 10 mg of recombinant soluble
Ly6d, (D) anti-Ly6d antibody then splenic B
cells, or (E) control isotype antibody then
splenic B cells. Plasmid pCDM8±transfected
COS cells were incubated with (F) splenic B
cells. Ly6d1 COS cells were also incubated
with (G) splenic T cells, (H) splenic T cells
preincubated with 10 mg of recombinant solu-
ble Ly6d, (I) anti-Ly6d antibody then splenic
T cells, or (J) control isotype antibody then
splenic T cells. Plasmid pCDM8±transfected
COS cells were incubated with (K) splenic T
cells. Binding was examined by light micros-
copy (1003).
is also no O-glycosylation of recombinant Ly6d. The Ly6d cDNA isolated encodes a 76±amino acid (9
kDa) protein that has interesting features. First, usingA problem in isolating the Ly6d ligand was the poten-
tial low-affinity binding between Ly6d and Ly6d-L, as Kyte-Doolittle hydrophobicity profiles, Ly6d-L was shown
to lack a hydrophobic leader sequence and thereforeprevious studies showed that interactions between leu-
kocyte cell surface molecules and their ligands are tran- was unlikely to be a typical type I integral membrane
protein. This suggested that Ly6d was a type II integralsient, of low affinity (e.g., the CD2±CD48 interaction in
rat, Ka 5 1.1 3 104 M21), with rapid dissociation rates membrane protein, the features of which include a trans-
membrane sequence but lack a leader sequence (Bar-(van der Merwe et al., 1994). Our earlier experiments,
where the binding of monomeric Ly6d to lymphocytes clay et al., 1997). However, the potential transmembrane
region of Ly6d-L (,20 amino acids) is shorter than thecould not detected, demonstrated that the affinity of
Ly6d and Ly6d-L was likely to be low. To increase the typical 25±amino acid transmembrane hydrophobic se-
quence and, in addition, contains three highly chargedaffinity, multimeric Ly6d fluorescent microspheres were
constructed by coupling the FLAG-tagged recombinant residues (Gln25 and Arg30 and His31) between charged
residues Arg20 and Asp40, therefore making it unlikely toprotein with biotinylated anti-FLAG to 40 nm streptavidin
fluorescent microspheres. The binding of microspheres be a transmembrane region. In the exceptions where the
transmembrane sequence does contain some chargedindicated the presence of a cell surface ligand (Ly6d-L)
on 90% of thymocytes and 73% of splenocytes, and residues, the transmembrane sequence is usually asso-
ciated with transmembrane regions of other cell surfacethese cells were used as the source of cDNA to isolate
the ligand. The same recombinant protein was used proteins to form a multimeric complex in the membrane,
e.g., TCR/CD3 and CD89 (Barclay, 1997). However, posi-in a cDNA-transfected COS cell expression system to
isolate the cDNA for Ly6d-L. tive cell surface staining of COS cells transfected with
Immunity
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There were several other mechanisms by which
Ly6d-L could be retained on the cell surface. Ly6d-L
could be secreted and then loosely associated with the
cell membrane, or Ly6d-L could be like b-2-microglob-
ulin, which is noncovalenty associated with MHC class
I proteins (Stern and Wiley, 1994). Cell surface biotinyla-
tion, immunoprecipitation, and SDS-PAGE showed that
Ly6d-L is associated on the cell surface, either cova-
lently or noncovalently, with a 30 kDa protein whose
identity remains to be determined.
The mechanism by which Ly6d-L attaches to the cell
may be similar to that of other leukocyte cell surface
proteins, such as the cell adhesion molecule GlyCAM-1,
Mac-2, and its S-type lectin ligand, Mac-2-BP (Barclay
et al., 1997). These proteins are found on the cell surface
but have no obvious transmembrane sequence or site
for the attachment of a GPI anchor and are presumably
associated with other cell surface molecules; this type
of cell surface attachment is found in less than 1% of
all leukocyte cell surface proteins (Barclay et al., 1997).
It was of interest to find that Ly6d-L has a 52% amino
acid homology with an EGF repeat of the mouse neuro-
genic locus Notch protein. The Notch gene encodes a
type I cell surface protein and includes Notch in Dro-
sophila, Lin-12 and GLP-1 in C. elegans, and mNotch
(Motch A and Motch B) in the mouse (Weinmaster, 1997).
The two mouse Notch homologs, Motch A and Motch
B, have a similar tissue distribution to Ly6d-L (Lardelli
Figure 7. Western Analysis of Ly6d-L-Transfected COS Cells and Lendahl, 1993). Notch is a 300 kDa receptor for
(A) Reducing SDS-PAGE (Western) analysis in 15% acrylamide gels membrane-tethered ligands of the DSL (Delta/Serrate/
with supernatants (S) or lysates (L) from Ly6d-L-transfected COS lag-2) family of genes that encode ligands that bind and
cells (lanes 1±4) or CD48-transfected COS cells (lanes 5±8), which activate Notch (Lendahl, 1998), which is implicated in T
were treated (plus signs) or untreated (minus signs) with 10 mU
cell development by being involved in their rescue fromPIPLC. Samples from control mock±transfected cells are also shown
apoptosis (von Boehmer, 1997). Notch mediates cell±(lanes 9±12).
cell communications that are required for cell fate deci-(B) Nonreducing SDS-PAGE analysis in 15% acrylamide gels with
samples of the media from three separate wells of Ly6d-L-trans- sions in development (von Boehmer, 1997). A major fea-
fected COS cells (lanes 1±3) and 2 ml (diluted 1:10) of Ly6d-L COS ture of Notch is the tandem repeats of EGF-like modules,
cell lysate (lane 4). Detection in (A) and (B) was performed with anti- which have been implicated to interact with multiple
FLAG antibody followed by ECL.
ligands (Lendahl, 1998). The EGF module, which is 40(C) Reducing and nonreducing SDS-PAGE analysis in 15% acryl-
amino acids in length, is found in the extracellular do-amide gels with samples from Ly6d-L or mock-transfected COS
main of a wide variety of different molecules, includingcells that were cell surface labeled with biotin. Cells were lysed and
immunoprecipitated with the following monoclonal antibody prior those involved in blood coagulation, complement, and
to loading on gels. Lane 1: mock (control plasmid)-transfected COS the extracellular matrix. EGF modules are thought be
cells, anti-FLAG; lane 2: Ly6d-L transfection, control isotype anti- involved in ligand binding and can bind to receptors on
body; and lane 3: Ly6d-L transfection, anti-FLAG. Detection in the the surface or mediate interactions via their bound Ca21
left-hand side panels was performed with streptavidin-HRP followed
ion (Campbell, 1998). Furthermore, the EGF-like motif isby ECL reagent, as indicated. The same samples were then detected
found in the ligands of several Ly6-related moleculeson the right-hand side panels with anti-FLAG. Lane 4: Ly6d-L trans-
such as human CD59, human uPA-R, and mouse uPA-Rfection, anti-FLAG; lane 5: mock (control plasmid)-transfected COS
cells, anti-FLAG; and lane 6: Ly6d-L transfection, control isotype (Suh et al., 1994), and it is possible that the EGF-like
antibody. sequence of Ly6d-L is the binding domain for Ly6d. As
Ly6d-L and the EGF repeat sequences are similar, it is
also possible that Ly6d and Ly6d-L are involved in cell
N-FLAG-tagged Ly6d-L cDNA or C-FLAG-tagged Ly6d-L development and adhesion. Indeed, a human Ly6d ho-
cDNA clearly indicated that the protein is not inserted molog, E48, found in keratinocytes has adhesion proper-
into the cell membrane since both the N and C termini ties (Brakenhoff et al., 1995), and the overexpression
are on the outside of the cell. Thus, Ly6d-L is not a type of intrathymic Ly6A.2 leads to cell adhesion through
I, type II, or type III transmembrane protein, and further, binding an unidentified ligand (Bamezai and Rock,
there was no evidence that Ly6d-L is secreted since the 1995). Further, SLURP-1, the first identified secreted
cell media from COS cell transfectants did not contain member of the Ly6 family (Adermann et al., 1999) and
Ly6d-L. The final possibility that Ly6d-L is anchored to Ly6H, found in brain and leukemic cells (Horie et al.,
the plasma membrane by a GPI tail (type V) was ex- 1998; Apostolopoulos et al., 1999), are also involved in
cluded by the absence of motifs typical of GPI anchoring cellular interactions. However, the cellular interactions
and the results from PIPLC digestion of Ly6d-L-trans- are unlikely to be restricted to lymphocytes, as there is
broad expression of the Ly6d ligand, indeed broaderfected COS cells.
Ly6d-L, a Ligand for Mouse Ly6d
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ml, Kodak) for 1 hr at RT, washed, incubated with 50 ml of a streptavi-than that of Ly6d itself. In this light, Ly6d-L may react
din-horse radish peroxidase (Pierce) for 0.5 hr at RT before addingwith molecules other than Ly6d itself. The sequence
the substrate TMB and spectrophotometric quantization. Westernhomology to Notch indicates a possible role for Ly6d-L
analysis (SDS-PAGE) was performed using 15% acrylamide gels,
in multiple physiological processes, and the unusual as described previously (Apostolopoulos et al., 1996). Briefly, routine
mechanism by which Ly6d-L attaches to the cell surface detection was performed by incubating blots with anti-FLAG mono-
clonal antibody (1:2,000), washing, and incubating with rat anti-may indicate a unique role for this type of protein in cell
mouse Ig-HRP (1:10,000) and ECL. Lysates were prepared with ainteractions.
NP-40 lysis buffer containing a cocktail of protease inhibitors (0.5%
NP-40, 1 mM PMSF, 0.5% aprotinin, 0.5% sodium azide, 10 mM TrisExperimental Procedures
[pH 7.4] 150 mM NaCl). Treatment with 15 mU of PIPLC (Boehringer
Mannheim) was performed in transfected COS cells, which wereCells
previously washed and resuspended in 0.5 ml PBS for 1 hr at 378C.Thymocytes and splenocytes were isolated from 4- to 5-week-old
Biotinylation of cell surface proteins was performed by using EZ-linkC57BL/6 mice. B and T cells were recovered in warm DMEM/10%
sulfo-NHS-LC-Biotin (Pierce). Briefly, transfected COS cells wereFCS, spun for 5 min at 350 3 g, followed by lysis in 0.84 M NH4Cl washed twice in ice-cold PBS (1 mM MgCl2/0.1 mM CaCl2), followedfor 5 min at 378C. The cells were then spun 10 min at 350 3 g,
by incubation with 0.5 mg/ml EZ-link sulfo-NHS-LC-Biotin at 48Cwashed in warm DMEM, spun 5 min at 350 3 g, and resuspended
for 30 min. The biotin was removed and the cells were incubatedin 4 ml of DMEM/10% FCS. The cells were then added dropwise in
for 10 min in ice-cold DMEM. The cells were then washed twice ina sterile nylon wool column, followed by 1 ml of warm DMEM/10%
ice-cold PBS (1 mM MgCl2/0.1 mM CaCl2) and removed from theFCS. The column was then capped and incubated for 45 min at
plate, lysed (in a solution containing 0.5% nonident P-40, 1 mM378C with 2 ml of DMEM/10% FCS. Pure T cells were collected by
PMSF, 0.5% aprotinin, 0.5% sodium azide, 10 mM Tris [pH 7.4], andelution with 13 ml of warm DMEM/10% FCS. B cells were recovered
150 mM NaCl), immunoprecipitated with anti-FLAG (30 mg/ml) andby adding 2 ml of FCS to the nylon wool column and incubating for
protein A-sepharose followed by SDS-PAGE, as described earlier.60 min at RT. Following incubation, the column was washed with
50 ml of 10% FCS in PBS while the wool was gently teased apart
COS Cell Expression Systemwith an applicator stick. The effluent was then washed twice. The
Cloning of the Ly6d-L was performed by transfecting COS cells withpurity of the T cell and B cell preparations was determined by FACS
a mouse thymus pHM3 cDNA library and spleen pCDM8 cDNAanalysis using the following specific antibodies: T cells, anti-CD3;
library (Gumley et al., 1995) and by panning with 10 mg of recombi-B cells, anti-CD45R. Ly6d1 and Ly6d2 cells in these populations
nant soluble Ly6d monomer coated onto panning dishes, similar towere detected by staining with anti-Ly6d antibodies. Control cells
that described previously (Seed and Aruffo, 1987). COS cells werewere incubated with an irrelevant isotype monoclonal antibody. The
maintained in Dulbecco's modified Eagles Medium (DMEM, Cyto-Sf21 insect cell line (Clontech) was maintained at 278C in Grace's
systems Pty. Ltd., Castle Hill, NSW, Australia) and supplementedinsect cell culture medium (GIBCO±BRL) supplemented with 10%
with Fetal Clone II (Hyclone, Utah) and transfected using the DEAE-(v/v) FBS (Cytosystems, NSW, Australia).
dextran method (Vaughan et al., 1991). Forty-eight hours later, cells
were examined for cell surface expression of the ligands with theSubcloning Murine cDNA into a Baculovirus Vector
multimeric Ly6d fluorescent microspheres or with lymphocytes andThe cDNA for Ly6d was modified by PCR to produce soluble forms
the binding protocol described below. Localization of the cell sur-by the following: (1) removing the GPI anchoring sequence (Leu96-
face expression of Ly6d-L was performed by transfection of COSLeu128 of Ly6d [Gumley et al., 1995]); (2) adding a C-terminal His6
cells with either an N-terminal or C-terminal FLAG-tagged Ly6d-Ltag for purification; and (3) adding a FLAG fusion octapeptide (Asp-
construct, as described above, followed by incubation with mouseTyr-Lys-Asp-Asp-Asp-Asp-Lys) C-terminal to the His6 tag to enable
anti-FLAG monoclonal antibodies (1:500) in PBS/0.5% BSA and thendetection by Western analysis. PCR primers were used to add 59
rat anti-mouse Ig-FITC (1:100) in PBS/0.5% BSA. Ly6d transfectionsEcoRI and 39 BglII restriction sites on their termini. The PCR frag-
were performed with the full-length mouse Ly6d cDNA clone (Gum-ments were purified from agarose gels, ligated into EcoRI- and
ley et al., 1992), while mock transfections were performed with con-BglII-digested pHFBgl baculovirus transfer vector (Dr. Chris Parish,
trol plasmid (pCDM8) alone.A.N.U., Canberra, Australia), and transformed into subcloning effi-
ciency DH5-a cells (GIBCO±BRL). Single colonies were picked and
plasmid DNA isolated, purified with Chromaspin-200 columns (Clon- Multimeric Microspheres and Binding Studies
tech), and correct orientation of the cDNA in the recombinant vector To detect Ly6d-L, multimeric Ly6d microspheres were prepared
verified by asymmetric restriction enzyme analysis and by PCR. The by incubating 5 mg of soluble recombinant Ly6d protein, 5 mg of
construction of recombinant viral expression vectors, isolation of biotinylated anti-FLAG monoclonal antibody (Kodak), and 5 3 107
recombinant viruses, virus propagation and amplification, and char- streptavidin-labeled 40 nm fluorospheres (previously sonicated in
acterization of recombinant gene expression were performed as BlockAid blocking solution, Molecular Probes) for 1 hr at 48C. These
described elsewhere (Apostolopoulos et al., 1996). complexes were then added to 1 3 106 lymphocytes for 1 hr at 48C.
This mixture was then washed twice gently with PBS/0.5% BSA.
Purification of Proteins by Metal Chelation and Size The percentage of cells binding to microspheres was determined
Exclusion FPLC microscopically (2003 magnification) by dividing the number of cells
Recombinant proteins were purified using the His6 tag with Talon binding microspheres by the number of total cells in each field
resin (Clontech) and the native buffer protocol provided, followed (SEM). For blocking studies, antibodies were incubated with the
by size exclusion chromatography (FPLC) on a calibrated Sephacryl- microspheres for 1 hr at 48C prior to their addition to cells. As
100 column equilibrated with 20 mM HEPES, 2 mM EDTA (pH 7.4), controls, recombinant murine CD-48 and GFP were made in the
and buffer. The fractions containing each protein were collected, baculovirus system. Binding studies of COS cells with splenocytes
analyzed by SDS-PAGE by silver staining, and then used for further or thymocytes included transfection of COS cells with Ly6d-L or
studies. Ly6d cDNA (as described above), followed by incubation with lym-
phocytes for 0.5 hr at RT. Following binding, cells were then washed
five times with PBS/0.5% BSA, and binding on the cells was exam-Characterization of Proteins
Recombinant proteins were identified by ELISA: 50 ml of a mono- ined microscopically. In blocking studies (using anti-ThB [Ly6d] 53-
9.2) and controls (using irrelevant isotype antibodies), antibodiesclonal anti-Ly6d mAb (12 mg/ml) in assay buffer was plated onto a
96-well ELISA plate (Nunc Immunopure Maxisorb, Rockilde, Den- were incubated with lymphocytes or multimeric microspheres for 1
hr at 48C prior to incubation with COS cells. Competitive inhibitionmark) for 1.5 hr at RT, the plate washed 6 times with 0.5% Tween
20 in PBS, and blocked with 2% BSA for 1 hr at RT. Fifty microliters of multimeric Ly6d microsphere binding was performed by preincu-
bating Ly6d-L transfected COS cells (0.5 hr at RT) or lymphocytesof cell supernatant from cultures was added, incubated for 1 hr at
RT, washed, and incubated with 50 ml of anti-FLAG-biotin (3.6 mg/ (1 hr at 48C) with 10 mg of recombinant soluble Ly6d, followed by
Immunity
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washing, as described above. The optimum incubation times for T cells by activating integrin-dependent adhesion pathways. Proc.
Natl. Acad. Sci. USA 94, 6898±6903.these assays were determined empirically. All binding assays were
performed in triplicate. Hogarth, P.M., Houlden, B.A., Latham, S.E., Sutton, V.R., and Mc-
Kenzie, I.F.C. (1984). Definition of new alloantigens encoded genes
Northern and Southern Blot Analysis in the Ly6 complex. Immunogenetics 20, 57±69.
Total RNA was isolated from C57BL/6 mice using a Qiagen RNeasy Horie, M., Okutomi, K., Taniguchi, Y., Ohbuchi, Y., Suzuki, M., and
Total RNA kit. Total RNA (10 mg) was loaded on a 1% agarose- Takahashi, E. (1998). Isolation and characterization of a new member
formaldehyde gel with electrophoresis at 15 V overnight and trans- of the human Ly6 gene family (Ly6H). Genomics 53, 365±368.
ferred to Hybond N. Blots were baked, prehybridized, and hybridized
Izon, D.J., Oritani, K., Hamel, M., Calvo, C.R., Boyd, R.L., Kincade,
with 32P-labeled Ly6d-L cDNA or 32P-labeled g-actin cDNA overnight
P.W., and Kruisbeek, A.M. (1996). Identification and functional analy-
at 428C, washed (Apostolopoulos et al., 1996), and then scanned
sis of Ly-6A/E as a thymic and bone marrow stromal antigen. J.
on a Molecular Dynamics Storm 840 Imager. Genomic DNA was
Immunol. 156, 2391±2399.
isolated from C57BL/6 mice using a Puregene kit (Gentra) and DNA
Kimura, S., Tada, N., Liu-Lam, Y., and Hammerling, U. (1984). Studieselectrophoresis on a 1% agarose gel and transferred to Hybond N1,
of the mouse Ly-6 alloantigen system. II: complexities of the Ly-6hybridized with 32P-labeled Ly6d-L cDNA overnight at 428C, and
region. Immunogenetics 20, 47±56.washed. The blots were then scanned on a Molecular Dynamics
Lardelli, M., and Lendahl, U. (1993). Motch A and motch BÐtwoStorm 840 Imager.
mouse Notch homologues coexpressed in a wide variety of tissues.
Exp. Cell Res. 204, 364±372.Received August 10, 1999; revised December 27, 1999.
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